The Technical Analyst
Vapotherm Inc [VAPO]
Exchange: NYSE Sector: Healthcare Industry: Medical - Devices
Vapotherm Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
5.68% $1.255
America/New_York / 8 mai 2024 @ 13:55
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7.80 mill |
| EPS: | -9.64 |
| P/E: | -0.130 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 6.21 mill |
| Avg Daily Volume: | 0.0078 mill |
| RATING 2024-05-08 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.130 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.130 | industry: PE 87.83 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.136 - 1.374 ( +/- 9.48%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-27 | Mckay Dorota | Buy | 2 275 | Stock Option (right to buy) |
| 2024-02-27 | Mckay Dorota | Buy | 1 750 | Stock Option (right to buy) |
| 2024-02-27 | Mckay Dorota | Buy | 1 300 | Stock Option (right to buy) |
| 2024-02-27 | Mckay Dorota | Sell | 1 750 | Stock Option (right to buy) |
| 2024-02-27 | Mckay Dorota | Sell | 1 300 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 93.57 |
| Last 97 transactions |
| Buy: 4 193 517 | Sell: 68 939 |
Forecast:
15:35 - $1.208
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $1.255 (5.68% ) |
| Volume | 0.0003 mill |
| Avg. Vol. | 0.0078 mill |
| % of Avg. Vol | 3.29 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VAPO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
VAPO
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol medication; and tracheostomy adaptors. In addition, Vapotherm, Inc. offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.
Latest Press Releases
2024-03-20 08:30:00 - Press Release
Onymos And Vapotherm Announce Partnership To Create An End-to-end Internet Of Medical Things Solution (iomt)
Partnership enables vapotherm to build a robust and secure solution 80% faster than the standard development timeline to meet data visualization and device management goals for hvt® 2.0 and future home system san francisco , march 20, 2024 /prnewswire/ -- onymos , developer of the world's first features-as-a-service platform, and vapotherm, inc. (otcqx: vapo), ("vapotherm"), a global medical technology company whose proprietary high-velocity therapy® products treat patients of all ages suffering from respiratory distress, today announced the formation of a development and commercialization partnership. this partnership will help vapotherm create a unique respiratory digital platform to meet its data visualization and device management goals for the vapotherm hvt® 2...
2024-03-15 07:36:00 - Press Release
Vapotherm To Unveil Access365 Home Ventilation Solution At Medtrade
Exeter, n.h. , march 15, 2024 /prnewswire/ -- vapotherm, inc., (otcqx: vapo), ("vapotherm" or the "company") today announced the debut of its access365™ home ventilation solution at the upcoming medtrade conference.
2024-03-06 06:45:00 - Press Release
Dr. David Yamane Was Awarded The Star Research Award At The 2024 Critical Care Congress For The Presentation Of The Hyperact Study - A Randomized Controlled Trial Demonstrating Vapotherm's High Velocity Therapy Effectively Treats Moderate-severe Acute Exacerbations Of Copd, While Improving Patient Comfort
Exeter, n.h. , march 6, 2024 /prnewswire/ -- vapotherm, inc. (otcqx: vapo), ("vapotherm" or the "company") today announced that david yamane, md was awarded the star research award by the society for critical care medicine (sccm) at the 2024 critical care congress.
2024-02-29 06:45:00 - Press Release
Vapotherm's Hvt 2.0 System Overcomes Regulatory Hurdles For Entry Into South America's Largest Health Care Market
Exeter, n.h. , feb. 29, 2024 /prnewswire/ -- vapotherm, inc. (otcqx: vapo), ("vapotherm" or the "company"), a global medical technology company specializing in the development and commercialization of its proprietary vapotherm high-velocity therapy® products for patients of all ages experiencing respiratory distress, is pleased to announce the regulatory approval of the hvt 2.0 system in brazil.
2024-02-22 16:10:00 - Press Release
Vapotherm Reports Fourth Quarter And Fiscal Year 2023 Financial Results
Exeter, n.h. , feb. 22, 2024 /prnewswire/ -- vapotherm, inc. (otcqx: vapo), ("vapotherm" or the "company"), today announced fourth quarter and fiscal year 2023 financial results and related highlights.
Latest News
2023-11-08 23:02:01 - Seeking Alpha
Vapotherm, Inc. (VAPO) Q3 2023 Earnings Call Transcript
Vapotherm, Inc. (NYSE:VAPO ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Dorota Mckay - VP and CAO Joe Army - President and CEO John Landry - SVP and CFO Conference Call Participants Macauley Kilbane - William Blair Marie Thibault - BTIG Operator Good afternoon, and welcome to Vapotherm's Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] It is now my pleasure to turn today's conference over to Dorota Mckay, Vapotherm's Vice President and Chief Accounting Officer.
2023-11-02 14:34:56 - InvestorPlace
3 Stocks Set to Rocket When the Bears Get Short-Squeezed
Federal Reserve officials kept current interest rate levels unchanged on Wednesday. Investors and economists will be diligently scrutinizing any hints and clues offered during this meeting, specifically regarding the long-term stability of rates and whether central bankers still view future increases as necessary in the coming months.
2023-11-01 06:45:00 - PRNewsWire
Vapotherm To Report Third Quarter 2023 Financial Results
EXETER, N.H. , Nov. 1, 2023 /PRNewswire/ -- Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the third quarter of 2023 after the close of trading on Wednesday, November 8, 2023.
2023-08-08 23:04:02 - Seeking Alpha
Vapotherm, Inc. (VAPO) Q2 2023 Earnings Call Transcript
Vapotherm, Inc. (NYSE:VAPO ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Mark Klausner - ICR Westwicke, IR Joe Army - President and CEO John Landry - SVP and CFO Conference Call Participants Jon Young - Canaccord Margaret Kaczor - William Blair Operator Thank you for standing by. My name is Greg, and I will be your conference operator today.
2023-08-08 21:11:30 - Zacks Investment Research
Vapotherm (VAPO) Reports Q2 Loss, Misses Revenue Estimates
Vapotherm (VAPO) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.84 per share a year ago.
2023-05-06 00:08:04 - Seeking Alpha
Vapotherm, Inc. (VAPO) Q1 2023 Earnings Call Transcript
Vapotherm, Inc. (NYSE:VAPO ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Mark Klausner - ICR Westwicke, IR Joe Army - President and CEO John Landry - Senior Vice President and CFO Conference Call Participants Margaret Kaczor - William Blair Zachary Day - Canaccord Genuity Jason Bednar - Piper Sandler Sam Eiber - BTIG Operator Good afternoon, and welcome to the Vapotherm, Inc. First Quarter 2023 Financial Results Conference Call. [Operator Instructions] I will now turn the conference over to Mark Klausner.
2023-03-26 14:16:58 - InvestorPlace
7 Stocks to Sell in March Before They Crash and Burn
While there's something romantic about taking a shot on an underappreciated enterprise, a countervailing narrative also exists, which brings us to the topic of stocks to sell. To be sure, very few people enjoy discussing this subject (especially if you own the shares mentioned).
2023-02-28 06:01:23 - MarketBeat
3 Penny Stocks The Insiders Are Buying
Penny stocks come with many risks, but with those risks come the potential for great rewards. While there is no guarantee which penny stocks will deliver those rewards, following the insiders is 1 way to find them.
2023-02-23 20:19:04 - Zacks Investment Research
Vapotherm (VAPO) Reports Q4 Loss, Tops Revenue Estimates
Vapotherm (VAPO) delivered earnings and revenue surprises of 6.33% and 0.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2023-02-23 18:15:05 - Seeking Alpha
Vapotherm, Inc. (VAPO) Q4 2022 Earnings Call Transcript
Vapotherm, Inc. (NYSE:VAPO ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Mark Klausner - ICR Westwicke, IR Joe Army - President and CEO John Landry - Senior Vice President and CFO Conference Call Participants Zachary Day - Canaccord Genuity Sam Eiber - BTIG Operator Good afternoon. And welcome to Vapotherm's Fourth Quarter 2022 Financial Results Conference Call.